Ozone autohemotherapy is a clinic procedure that draws blood, briefly mixes it with ozone gas and returns it, aiming to trigger the body's own defense and repair systems. The most consistent human evidence concerns nerve pain after shingles and sleep in chronic pain. Serious harms appear rare in controlled studies but are real and depend heavily on clinic practice. For healthy people seeking longer, healthier lives, the case is unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| G6PD activity | Within laboratory reference range (normal activity) | Rules out an enzyme deficiency that leaves red cells prone to rupture |
| Hemoglobin | Men 14–16 g/dL; women 13–15 g/dL | Detects red-cell loss or rupture |
| Platelet count | 200,000–350,000/µL | Detects bleeding risk |
| Potassium | 4.0–4.5 mmol/L | Detects dangerously high blood potassium from red-cell rupture |
| eGFR | Above 90 mL/min/1.73 m² | Gauges ability to clear potassium |
| hs-CRP | Below 1.0 mg/L | Tracks inflammation; high values predicted better response |
| TSH | 1.0–2.0 mIU/L | Excludes overactive thyroid |
| LDL cholesterol | Below 100 mg/dL (below 70 mg/dL if high cardiovascular risk) | Tracks the cholesterol effect reported in one small study |
| Hepatitis B, hepatitis C and HIV serology | Negative | Documents baseline and detects clinic-acquired infection |
| Red-cell glutathione | No established target; track change from own baseline | Detects possible antioxidant depletion |
Cadence: Baseline testing before a first course (G6PD once); potassium and complete blood count after the first 3–5 sessions, at the end of each 10–15-session course, then every 3–6 months during maintenance; inflammation and cholesterol at course end and every 6–12 months; bloodborne-virus tests yearly with repeated sessions; potassium on treatment days with kidney disease or potassium-raising drugs.